Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus NORMOZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus NORMOZIDE.
ALDORIL 25 vs NORMOZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Oral: 10 mg once daily. Maximum dose: 20 mg once daily.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min). Clinical context: Dosing interval adjustments are required in renal disease to avoid accumulation.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Renal excretion accounts for approximately 70% of elimination (30% as unchanged drug, 40% as inactive metabolites). Biliary/fecal elimination constitutes about 25%, with the remainder undergoing metabolic clearance.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination